Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 3
1997 1
1998 4
1999 4
2000 3
2001 5
2002 5
2003 7
2004 8
2005 5
2006 10
2007 13
2008 9
2009 10
2010 15
2011 18
2012 13
2013 17
2014 12
2015 22
2016 19
2017 26
2018 15
2019 16
2020 22
2021 36
2022 28
2023 28
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

330 results

Results by year

Filters applied: . Clear all
Page 1
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. Farge D, et al. Among authors: ikezoe t. Lancet Oncol. 2022 Jul;23(7):e334-e347. doi: 10.1016/S1470-2045(22)00160-7. Lancet Oncol. 2022. PMID: 35772465 Free PMC article. Review.
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Dinh M, Soong D, Noguchi H, Buchbjerg JK, Favaro E, Fukuhara N. Izutsu K, et al. Among authors: ikezoe t. Cancer Sci. 2023 Dec;114(12):4643-4653. doi: 10.1111/cas.15996. Epub 2023 Nov 3. Cancer Sci. 2023. PMID: 37921363 Free PMC article.
[Overview].
Ikezoe T. Ikezoe T. Rinsho Ketsueki. 2019;60(6):646. doi: 10.11406/rinketsu.60.646. Rinsho Ketsueki. 2019. PMID: 31281157 Japanese. No abstract available.
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Suzuki K, Wechalekar AD, Kim K, Shimazaki C, Kim JS, Ikezoe T, Min CK, Zhou F, Cai Z, Chen X, Iida S, Katoh N, Fujisaki T, Shin HJ, Tran N, Qin X, Vasey SY, Tromp B, Weiss BM, Comenzo RL, Kastritis E, Lu J. Suzuki K, et al. Among authors: ikezoe t. Ann Hematol. 2023 Apr;102(4):863-876. doi: 10.1007/s00277-023-05090-z. Epub 2023 Mar 2. Ann Hematol. 2023. PMID: 36862168 Free PMC article. Clinical Trial.
A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results.
Wasserstein M, Lachmann R, Hollak C, Arash-Kaps L, Barbato A, Gallagher RC, Giugliani R, Guelbert NB, Ikezoe T, Lidove O, Mabe P, Mengel E, Scarpa M, Senates E, Tchan M, Villarrubia J, Chen Y, Furey S, Thurberg BL, Zaher A, Kumar M. Wasserstein M, et al. Among authors: ikezoe t. Genet Med. 2022 Jul;24(7):1425-1436. doi: 10.1016/j.gim.2022.03.021. Epub 2022 Apr 26. Genet Med. 2022. PMID: 35471153 Free article. Clinical Trial.
[Overview].
Ikezoe T. Ikezoe T. Rinsho Ketsueki. 2023;64(5):376. doi: 10.11406/rinketsu.64.376. Rinsho Ketsueki. 2023. PMID: 37271528 Japanese. No abstract available.
Effects of Low-Intensity Torque-Matched Isometric Training at Long and Short Muscle Lengths of the Hamstrings on Muscle Strength and Hypertrophy: A Randomized Controlled Study.
Nakao S, Ikezoe T, Taniguchi M, Motomura Y, Hirono T, Nojiri S, Hayashi R, Tanaka H, Ichihashi N. Nakao S, et al. Among authors: ikezoe t. J Strength Cond Res. 2023 Oct 1;37(10):1978-1984. doi: 10.1519/JSC.0000000000004510. J Strength Cond Res. 2023. PMID: 37729512 Clinical Trial.
330 results